StockData

Nordicus Partners Corp (NORD) stock

NORDNasdaqServices-Management Consulting ServicesFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Sep 28, 2026Score 4/30
$2.87+0.36 (+14.34%)

Close on Nov 16, 2026Market cap $55.80MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$55.80M
P/E ratio
–
Price to sales
–
Price to book
0.91
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$5.07M
EPS, diluted
-$0.28
Free cash flow
-$4.34M
Book value per share
$3.21
Diluted shares
19M

Trading

Previous close
$2.51
Open
$2.44
Day's range
$2.29 – $3.10
Volume
27,646
Average volume (20 days)
16,045
52-week range
$1.48 – $5.15
RSI (14 days)
40.9
Volatility (1 year)
208.3%
Relative volume
4.44×

Market cap history

Month-end market cap since 2015, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.

PeriodNORDS&P 500DifferenceNORD per yearS&P 500 per year
1 month-29.0%-3.1%−25.9 pts
3 months+6.3%-4.5%+10.7 pts
Year to date-42.6%+9.4%−52.0 pts
1 year-41.4%+11.3%−52.7 pts
3 years-64.1%+70.4%−134.5 pts-28.9%+19.4%
5 years-80.9%+68.6%−149.5 pts-28.2%+11.0%
10 years-87.9%+297.7%−385.6 pts-19.0%+14.8%

Fifteen years at a glance

Fiscal years 2012 to 2026 and trailing twelve months, USD

Revenue

–

Gross profit

–

Operating income

-$4.36M

Net income

-$5.07M

EPS, diluted

-$0.28

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Nordicus Partners filed with the SEC as exhibits to Form 8-K or 6-K

  1. News
  2. News
  3. News
  4. Update
  5. Update
  6. Update
All press releases and earnings

About Nordicus Partners

Services-Management Consulting Services

Nordicus Partners Corporation is a biotechnology firm that acquires and develops early-stage drug candidates focusing on inflammation and immune modulation. Its portfolio includes three preclinical research subsidiaries developing treatments for patients with oral disorders and inflammatory skin conditions. Orocidin A/S develops QR-01, an oral formulation for aggressive periodontitis. Bio-Convert A/S develops QR-02, a mucoadhesive oral gel for oral leukoplakia lesions. NoviThera ApS develops QR-04, a monoclonal antibody treatment for psoriasis. In addition, the firm holds a minority interest in a commercial real estate mortgage banking business.

Company profile, executives and history

Nordicus Partners stock: common questions

What is Nordicus Partners's stock price?

NORD closed at $2.87 on Nov 16, 2026, up 14.34% on the day. Over the past 52 weeks it traded between $1.48 and $5.15.

What is Nordicus Partners's market cap?

Nordicus Partners was worth $55.80M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.

What is NORD's P/E ratio?

Nordicus Partners lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.28), so it has no meaningful P/E ratio.

Does Nordicus Partners pay a dividend?

No. Nordicus Partners has not paid a cash dividend over the last twelve months.

How has NORD stock performed over the past year?

Including dividends, NORD returned -41.4% over the past year, against +11.3% for the S&P 500.

How many NORD shares are sold short?

0M shares were sold short at the latest FINRA report, 0.07% of the float, or 1.0 days of average trading volume.

Who are Nordicus Partners's competitors?

Companies most similar to Nordicus Partners by business, industry and size include BLNC, LEEN, GFLT, HSTA, BDTB.

See a number that looks wrong?